Itaconix’ interims highlight the meaningful commercial progress that has been made this year. The highlight to date, in our view, was the recent application agreement with AkzoNobel to evaluate and develop new chelates. We see this as a likely driver of revenue growth next year. Whilst some milestones have taken longer than anticipated, recent announcements suggest these are timing issues and significant medium term growth potential remains.